Innovative Medicine
-
New Category I CPT Codes and Payment Rates for Circulating Tumor Cell Testing Effective January 1
New codes granted in recognition of clinical efficacy -
-
-
-
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Data Show Overall Response of 68 Percent in Patients with Relapsed or Refractory Disease -
-
-
-
New Long-Term Study Suggests Lower Mortality in Alzheimer’s Patients Treated with Galantamine Versus Placebo
Significantly Lesser Cognitive Decline Also Seen in Treatment Group Compared to Placebo Group